| MET |
Report |
2Q26 adjusted EPS |
BEAT |
pred ~$2.33 vs. cons $2.30 |
MEDIUM |
| MET |
Report |
2Q26 variable investment income, pretax |
BEAT |
pred ~$250M vs. cons $245M |
HIGH |
| MET |
Report |
2Q26 Group Benefits adjusted earnings |
BEAT |
pred ~$432M vs. cons $420M |
MEDIUM |
| MET |
Guide |
Variable investment income |
UNCHANGED |
guide ~$1.60B vs. cons $1.60B (FY2026) |
MEDIUM |
| MET |
Guide |
Direct expense ratio |
UNCHANGED |
guide ~12.1% vs. cons 12.1% (FY2026) |
HIGH |
| MET |
Guide |
RIS adjusted earnings |
UNCHANGED |
guide ~$1.70B vs. cons $1.70B (FY2026 midpoint) |
MEDIUM |
| MET |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| MET |
Return |
5-day cumulative residual |
+0.8% (FADE) |
A modest EPS beat and clean Group Benefits underwriting support the initial move, but maintained FY2026 VII of ~$1.60B versus consensus ~$1.60B leaves limited out-period estimate upside; the required 2H26 VII catch-up remains about ~$837M versus consensus ~$837M, causing revisions to flatten and part of the day-1 gain to fade. |
MEDIUM |